Beyfortus (nirsevimab) / AstraZeneca, Sanofi - LARVOL DELTA

Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study. (PubMed, Lancet Infect Dis) - P | "Chile's nirsevimab immunisation strategy significantly reduced RSV-related LRTI hospitalisations and more severe cases requiring intensive care. Our findings indicate a broader public health impact, with reductions also observed in all-cause LRTI hospitalisations. These results might encourage other countries to advance RSV prevention efforts."

Journal • Observational data • Retrospective data • Critical care • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Respiratory Syncytial Virus: A Narrative Review of Updates and Recent Advances in Epidemiology, Pathogenesis, Diagnosis, Management and Prevention. (PubMed, J Clin Med) - "Non-pharmaceutical interventions, maternal vaccination, and prophylaxis with monoclonal antibodies, e.g., palivizumab and nirsevimab, a newly introduced long-acting agent, are efficient protective and preventive measures. Treatment is still, for the most part, supportive in nature and focuses on oxygen supplementation, hydration, and respiratory support for patients with more severe disease courses; however, the development of immunoprophylaxis and vaccine candidates shows promise for reducing the global burden of RSV."

Journal • Review • Asthma • Immunology • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Nirsevimab: a change of paradigm in the prophylaxis of Respiratory Syncytial Virus disease among infants. (PubMed, Ann Ig) - No abstract available

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Impact of Nirsevimab on bronchiolitis: reduction in hospitalizations and severity (ERS 2025) - No abstract available

Clinical • Pulmonary Disease • Respiratory Diseases

A paradigm shift in post-bronchiolitis recurrent wheezing: the dual impact of COVID-19 and Nirsevimab (ERS 2025) - No abstract available

Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Effectiveness of nirsevimab against RSV-related outcomes: findings of the 2024-2025 campaign in Catalonia align with previous analysis. (PubMed, Arch Dis Child) - No abstract available

Journal • Infectious Disease

Scenario Projections of Respiratory Syncytial Virus Hospitalizations Averted Due to New Immunizations. (PubMed, JAMA Netw Open) - "Respiratory syncytial virus vaccination for adults aged 60 years or older, maternal RSV vaccination, and long-acting monoclonal antibodies (nirsevimab) for infants younger than 8 months...In this decision analytical model of RSV immunizations, the results suggest a modest reduction in RSV-diagnosed hospitalizations during the 2023 to 2024 season due to limited availability of immunization products, particularly for infants. A higher uptake earlier in the season may lead to substantial reductions in RSV hospitalizations in the 2024 to 2025 season."

Journal • Respiratory Diseases • Respiratory Syncytial Virus Infections

Evaluation of pregnant women's knowledge about RSV and immunization attitudes before infant immunization with monoclonal antibodies in Turkey. (PubMed, J Trop Pediatr) - "A thorough literature review revealed no other studies assessing pregnant women's attitudes toward RSV mAb; it showed they would be more willing to accept it if included in Turkey's national vaccine programs. Further studies are needed globally to find if RSV vaccination rates increase if the benefits of infection protection and detailed information about the RSV vaccine are provided to mothers or families."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Demographic Characteristics Associated With Uptake of Neonatal Respiratory Syncytial Virus Prophylaxis. (PubMed, Mil Med) - "This study highlights the high uptake of RSV prophylaxis within a universal healthcare model and identifies the possibility of maternal service member status as a factor influencing uptake. The results suggest that the first month of life is a pivotal period for addressing gaps in RSV prophylaxis coverage. Although race did not significantly affect uptake, ongoing research is needed to explore barriers and refine strategies to optimize prevention efforts, particularly among dependent and retired populations. These findings underscore the role of universal health care in mitigating disparities and improving neonatal health outcomes."

Journal • Critical care • Respiratory Diseases • Respiratory Syncytial Virus Infections

Strategies to improve interprofessional communication regarding maternal and infant RSV immunization. (PubMed, Vaccine) - No abstract available

Journal • Respiratory Diseases • Respiratory Syncytial Virus Infections

Nirsevimab Provides Real-World RSV Protection in Infants. (PubMed, JAMA) - No abstract available

Journal • Real-world evidence

Intention to Use RSVpreF Vaccine or Nirsevimab to Prevent Infant RSV Among Pregnant Individuals. (PubMed, Pediatr Infect Dis J) - "Health communication interventions that increase awareness about RSV immunizations and highlight their safety, effectiveness and importance are needed to increase intended uptake."

Journal • CNS Disorders • Respiratory Diseases • Respiratory Syncytial Virus Infections

Respiratory syncytial virus prophylaxis for children in Africa: Challenges, opportunities and public health strategies. (PubMed, J Public Health Afr) - "Despite the introduction of maternal vaccines, such as RSVpreF (respiratory syncytial virus prefusion F protein vaccine), and monoclonal antibodies (mAbs), such as nirsevimab, barriers including high costs, infrastructure limitations, and vaccine hesitancy hinder implementation in African settings...A dual approach combining maternal vaccines with mAbs offers comprehensive protection, particularly for high-risk infants. By addressing these challenges and leveraging available opportunities, Africa can lead efforts to reduce RSV-associated morbidity and mortality, improving outcomes for its most vulnerable populations."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department. (PubMed, Enferm Infecc Microbiol Clin (Engl Ed)) - "The observed EIS was likely due to RSV immunization in infants' high coverage with good effectiveness and low influenza B circulation."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Turkish pediatricians' knowledge, attitudes, and awareness of respiratory syncytial virus (RSV) infection and immunization strategies: a cross-sectional study. (PubMed, Turk J Pediatr) - "The use of CXR and administration of non-evidence-based therapies in diagnosing and managing RSV illness were relatively high. Additionally, there is a notable gap in knowledge and awareness regarding the maternal RSV vaccine and nirsevimab."

Journal • Observational data • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "RSV immunization strategies would significantly reduce the disease burden in Panama. Nirsevimab would have a greater public health impact than RSVpreF due to its sustained efficacy and protection regardless of gestational age."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection (clinicaltrials.gov) - P=N/A | N=4350 | Active, not recruiting | Sponsor: Griffith University

New trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review. (PubMed, Vaccines (Basel)) - "Additionally, accelerating the introduction and administration of nirsevimab in developing countries remains imperative. Thus, this review comprehensively summarizes the administration of nirsevimab in infants to facilitate its broader application."

Journal • Review • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Impact of Nirsevimab immunoprophylaxis on professional exhaustion during two epidemics of respiratory syncytial virus. (PubMed, J Pediatr Nurs) - "The implementation of immunoprophylaxis against respiratory syncytial virus has not only improved patient outcomes but has also positively impacted the emotional well-being of pediatric healthcare providers, highlighting the importance of implementing preventive strategies to support healthcare professionals."

Clinical • Journal • Fatigue • Pediatrics • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Vectored long-term co-delivery of antibodies for SARS-CoV-2, RSV and Influenza prophylaxis. (PubMed, Virology) - "Further, we demonstrate that AAV8-vectored co-delivery of A23.58.1, alongside anti-RSV mAb Nirsevimab, and anti-Influenza mAb 1000-3B04, at a physiologically relevant level for viral protection, is possible. This approach could be a valuable alternative to mAb treatment in immunocompromised populations by conferring long-term antibody expression and prophylaxis following a single intramuscular injection. Further, co-delivery of several antibodies simultaneously demonstrates the feasibility of generating broad and robust antiviral gene therapies in the future."

Journal • Gene Therapies • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

"Maternal Perspectives on Decision-Making for Newborn RSV Prophylaxis with Nirsevimab". (PubMed, J Pediatric Infect Dis Soc) - No abstract available

Journal

Respiratory syncytial virus preventives for children in Australia: current landscape and future directions. (PubMed, Med J Aust) - "Previously, palivizumab, a costly, short-acting monoclonal antibody, was the primary preventive option. The recent introductions of nirsevimab (Beyfortus), a long-acting monoclonal antibody, and Abrysvo, a maternal RSV vaccine, have brought about significant advances in RSV prevention for children...Key logistical considerations include ensuring timely access and equitable distribution, particularly for First Nations populations who face increased risk from RSV infection. Coordinated efforts are essential to overcome health care disparities and deliver effective prevention strategies to these prioritised groups."

Journal • Review • Asthma • Immunology • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Health-care burden related to respiratory syncytial virus in a resource-constrained setting: a prospective observational study. (PubMed, Lancet Glob Health) - "RSV strains health care in Bangladesh, increasing mortality risks. Preventive interventions could lessen its impact, boosting health-care capacity and child health in resource-limited settings."

Journal • Observational data • Reimbursement • US reimbursement • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

PUBLIC HEALTH IMPACT OF NIRSEVIMAB AND REDUCTION OF RSV HOSPITALIZATION IN ALL INFANTS: EARLY REAL-WORLD DATA FROM TUSCANY REGION (ITALY) (ESPID 2025) - "Regarding out-of-season infants, the results showed a reduction in RSV hospitalization of 86.4% for those born between August-October and 77% for those born between April-July. Born between Apr-24 and Mar-25 in-season, Nov-24 and Mar-25 out-of-season, Apr-Oct-24 out-of-season, Apr-Jul-24 out-of-season, Aug-Oct 2024 2022-23 199 62 137 48 89 2023-24 182 70 112 39 73 Mean 2022-24 190.5 66 124.5 43.5 81 2024-25 31 10 21 10 11 Reduction (%) -83.7% -84.8% -83.1% -77.0% -86.4% Conclusions/Learning Points In conclusion, our real-world data demonstrate a significant public health impact of nirsevimab when the prevention strategy targets all infants at their first RSV season, both in-season and out-of-season, leading to a drastic reduction in RSV hospitalization in all infants."

Clinical • Real-world • Real-world evidence • Infectious Disease • Respiratory Syncytial Virus Infections

RSV BURDEN IN INFANTS ATTENDING HOSPITAL EMERGENCY DEPARTMENTS IN IBERIA FROM 2021 TO 2024. THE RHEDI PROSPECTIVE STUDY. (ESPID 2025) - "Background RSV burden is not well established in the emergency department(ED) where RSV testing is not systematic.After the SARS-CoV-2 pandemic, evolving patterns of epidemiology have been observed.The aim of this study is to describe the burden of RSV and other respiratory infections in children ≤ 2 years of age presenting to the ED.Nirsevimab for RSV prevention under 6 months was introduced in the immunization schedule in Spain September 2023 Method Prospective,hospital-based surveillance in EDs of eight pediatric hospitals in Spain and Portugal was carried out.Patients were recruited in three time periods:January-2022 to April 2022,September-2022 to April-2023 and,September-2023 to April-2024.During the ED visit,clinical and demographic data and nasopharyngeal sample for PCR-based microbiological analysis were collected from each participant.Comparison between RSV positive/negative patients was performed.Data was analyzed using RStudio 2024.12.0. Results 1.654..."

Clinical • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Syncytial Virus Infections